311 related articles for article (PubMed ID: 36045390)
1. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Pophali P; Desai SR; Shastri A
Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
[TBL] [Abstract][Full Text] [Related]
3. New agents in myelodysplastic syndromes.
Jabbour E; Giles FJ
Curr Hematol Malig Rep; 2006 Mar; 1(1):25-33. PubMed ID: 20425328
[TBL] [Abstract][Full Text] [Related]
4. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP; Zeidan AM
Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
[TBL] [Abstract][Full Text] [Related]
5. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
[TBL] [Abstract][Full Text] [Related]
7. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
8. New agents in myelodysplastic syndromes.
Jabbour EJ; Giles FJ
Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
[TBL] [Abstract][Full Text] [Related]
9. Evolving strategies in the treatment of MDS and AML.
Stone R; Sekeres M; Garcia-Manero G
Clin Adv Hematol Oncol; 2009 Aug; 7(8):1-14; quiz 2 p following 14. PubMed ID: 19927982
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment.
Marques FK; Sabino AP
Biomed Pharmacother; 2022 Dec; 156():113905. PubMed ID: 36306593
[TBL] [Abstract][Full Text] [Related]
11. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
Tavakkoli M; Chung SS; Park CY
Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
[TBL] [Abstract][Full Text] [Related]
12. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
13. Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
Madanat YF; Xie Z; Zeidan AM
Expert Rev Hematol; 2023 Jan; 16(1):51-63. PubMed ID: 36620919
[TBL] [Abstract][Full Text] [Related]
14. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
Stankov K; Stankov S; Katanic J
Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with lower-risk myelodysplastic syndromes.
Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
[TBL] [Abstract][Full Text] [Related]
16. [Updated treatment strategies for myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2022; 63(6):660-666. PubMed ID: 36184521
[TBL] [Abstract][Full Text] [Related]
17. Precision Medicine in Myeloid Malignancies: Hype or Hope?
Upadhyay Banskota S; Khanal N; Marar RI; Dhakal P; Bhatt VR
Curr Hematol Malig Rep; 2022 Dec; 17(6):217-227. PubMed ID: 35972641
[TBL] [Abstract][Full Text] [Related]
18. Therapy-related myelodysplastic syndromes in the genomics era.
Renneville A; Bernard E; Micol JB
Bull Cancer; 2023 Nov; 110(11):1129-1140. PubMed ID: 37391357
[TBL] [Abstract][Full Text] [Related]
19. Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia.
Woll PS; Yoshizato T; Hellström-Lindberg E; Fioretos T; Ebert BL; Jacobsen SEW
J Intern Med; 2022 Aug; 292(2):262-277. PubMed ID: 35822488
[TBL] [Abstract][Full Text] [Related]
20. Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia.
Putnam C; Kondeti L; Kesler M; Varney M
Biochem Cell Biol; 2023 Dec; 101(6):481-495. PubMed ID: 37566901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
